Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1629
This examiner grants 44% of resolved cases
Ibrahim D. Bori serves in Tech Center 1600 and Art Unit 1622, with 614 resolved cases. His allowance rate of 43.8% indicates a challenging environment for patent applicants. However, the interview lift of 38.9% is exceptionally high, suggesting that interviews are a critical tool for overcoming rejections and securing an allowance. This 38.9% lift is a significant metric in his profile. The median days to allowance is 1259, which reflects the time required for his granted cases to reach resolution.
With 614 resolved cases, the data provides a solid foundation for understanding his examination style. The 43.8% allowance rate highlights the difficulty of obtaining a patent here. The interview lift is a vital strategic consideration. The 1259-day median serves as a baseline for pendency. This information from Art Unit 1622 underscores the importance of direct communication as a primary method for achieving a favorable outcome in his docket.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18579135 | METHODS FOR HAIR GROWTH | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 17044684 | DIETARY BUTYRATE | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 16975043 | PARENTERAL FORMULATION MATERIALS AND METHODS FOR 40-O-CYCLIC HYDROCARBON ESTERS AND RELATED STRUCTURES | Non-Final OA | Biotronik AG |
| 17248254 | REDUCED INHALATION HAZARD OF QUATERNARY AMMONIUM COMPOUNDS-PH DRIVEN PHYSIOLOGICAL RESPONSE | Final Rejection | ECOLAB USA INC. |
| 17425894 | MITOCHONDRIA-TARGETED ISOKETAL/ISOLEVUGLANDIN SCAVENGERS | Final Rejection | Vanderbilt University |
| 18261590 | POWDEROUS COMPOSITION(II) | Final Rejection | DSM IP ASSETS B.V. |
| 18684645 | HETEROCYCLIC COMPOUNDS AS SEROTONIN (5-HT) 5-HT2A AND 5-HT2C RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Final Rejection | The Board of Regents of The University of Texas System |
| 18990489 | COMPOSITION FOR PROTECTING SKIN CONTAINING A THYMOL ESTER-BASED COMPOUND | Non-Final OA | Amorepacific Corporation |
| 18968486 | COMPOSITION FOR PROMOTING HAIR SPROUTING OR HAIR GROWTH CONTAINING A THYMOL ESTER-BASED COMPOUND | Non-Final OA | AMOREPACIFIC CORPORATION |
| 18690198 | COMBINED PHARMACEUTICAL COMPOSITION OF CDK4/6 INHIBITOR AND AROMATASE INHIBITOR | Final Rejection | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18726933 | USE OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE IN THE TREATMENT OF CONGENITAL MUSCULAR DYSTROPHIES | Non-Final OA | METROPHARM AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy